

TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
June 07, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Private Issuer

**Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of June, 2011

Commission File Number 0-16174

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Translation of registrant's name into English)

5 Basel Street, P.O. Box 3190

Petach Tikva 49131 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form
40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Website: www.tevapharm.com

Reinspection Date Scheduled for Jerusalem Facility

As an anticipated follow-up to the warning letter Teva received on January 31, 2011 and the subsequent corrective actions Teva implemented, the Food and Drug Administration Office of Compliance is scheduled to begin its re-inspection of Teva's Jerusalem facility on June 13, 2011.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TEVA
PHARMACEUTICAL
INDUSTRIES
LIMITED
(Registrant)

By: /s/ Eyal
 Desheh
 —
 Name: Eyal
 Desheh
 Title: Chief
 Financial
 Officer

Date: June 7, 2011

-3-